|
1
|
Houghton J and Wang TC: Helicobacter
pylori and gastric cancer: A new paradigm for
inflammation-associated epithelial cancers. Gastroenterology.
128:1567–1578. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ernst PB, Peura DA and Crowe SE: The
translation of Helicobacter pylori basic research to patient care.
Gastroenterology. 130:188–206. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu N, Wu Q, Wang Y, Sui H, Liu X, Zhou N,
Zhou L, Wang Y, Ye N, Fu X, et al: Helicobacter pylori promotes
VEGF expression via the p38 MAPKmediated COX2PGE2 pathway in MKN45
cells. Mol Med Rep. 10:2123–2129. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fu S, Ramanujam KS, Wong A, Fantry GT,
Drachenberg CB, James SP, Meltzer SJ and Wilson KT: Increased
expression and cellular localization of inducible nitric oxide
synthase and cyclooxygenase 2 in Helicobacter pylori gastritis.
Gastroenterology. 116:1319–1329. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Greenhough A, Smartt HJ, Moore AE, Roberts
HR, Williams AC, Paraskeva C and Kaidi A: The COX-2/PGE2 pathway:
Key roles in the hallmarks of cancer and adaptation to the tumour
microenvironment. Carcinogenesis. 30:377–386. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fujino H, Xu W and Regan JW: Prostaglandin
E2 induced functional expression of early growth response factor-1
by EP4, but not EP2, prostanoid receptors via the
phosphatidylinositol 3-kinase and extracellular signal-regulated
kinases. J Biol Chem. 278:12151–12156. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sheng H, Shao J, Washington MK and DuBois
RN: Prostaglandin E2 increases growth and motility of colorectal
carcinoma cells. J Biol Chem. 276:18075–18081. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pai R, Szabo IL, Soreghan BA, Atay S,
Kawanaka H and Tarnawski AS: PGE(2) stimulates VEGF expression in
endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys
Res Commun. 286:923–928. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tai HH: Prostaglandin catabolic enzymes as
tumor suppressors. Cancer Metastasis Rev. 30:409–417. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Na HK, Park JM, Lee HG, Lee HN, Myung SJ
and Surh YJ: 15-Hydroxyprostaglandin dehydrogenase as a novel
molecular target for cancer chemoprevention and therapy. Biochem
Pharmacol. 82:1352–1360. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ryu YM, Myung SJ, Park YS, Yang DH, Song
HJ, Jeong JY, Lee SM, Song M, Kim DH, Lee HJ, et al: Inhibition of
15-hydroxyprostaglandin dehydrogenase by Helicobacter pylori in
human gastric carcinogenesis. Cancer Prev Res (Phila). 6:349–359.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Myung SJ, Rerko RM, Yan M, Platzer P, Guda
K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, et al:
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of
colon tumorigenesis. Proc Natl Acad Sci USA. 103:12098–12102. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sitas F: Twenty five years since the first
prospective study by Forman et al (1991) on Helicobacter pylori and
stomach cancer risk. Cancer Epidemiol. 41:159–164. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang L, Wu WK, Gallo RL, Fang EF, Hu W,
Ling TK, Shen J, Chan RL, Lu L, Luo XM, et al: Critical role of
antimicrobial peptide cathelicidin for controlling Helicobacter
pylori survival and infection. J Immunol. 196:1799–1809. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Parsonnet J, Friedman GD, Vandersteen DP,
Chang Y, Vogelman JH, Orentreich N and Sibley RK: Helicobacter
pylori infection and the risk of gastric carcinoma. N Engl J Med.
325:1127–1131. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Peek RM Jr and Blaser MJ: Helicobacter
pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer.
2:28–37. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tanigawa T, Watanabe T, Hamaguchi M,
Sasaki E, Tominaga K, Fujiwara Y, Oshitani N, Matsumoto T, Higuchi
K and Arakawa T: Anti-inflammatory effect of two isoforms of COX in
H. pylori-induced gastritis in mice: Possible involvement of PGE2.
Am J Physiol Gastrointest Liver Physiol. 286:G148–G156. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pai R, Soreghan B, Szabo IL, Pavelka M,
Baatar D and Tarnawski AS: Prostaglandin E2 transactivates EGF
receptor: A novel mechanism for promoting colon cancer growth and
gastrointestinal hypertrophy. Nat Med. 8:289–293. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Society of Stomach Cancer of Chinese
Anti-Cancer Association, ; Society of Pathology of Chinese
Anti-Cancer Association; Chinese Society of Clinical Oncology, .
Chinese expert consensus on the molecular-targeted therapy for
HER-2-positive advanced gastric cancer. Zhonghua Zhong Liu Za Zhi.
35:315–319. 2013.(In Chinese). PubMed/NCBI
|
|
20
|
Ding Y, Tong M, Liu S, Moscow JA and Tai
HH: NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH)
behaves as a tumor suppressor in lung cancer. Carcinogenesis.
26:65–72. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wolf I, O'Kelly J, Rubinek T, Tong M,
Nguyen A, Lin BT, Tai HH, Karlan BY and Koeffler HP:
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of
human breast cancer. Cancer Res. 66:7818–7823. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pham H, Chen M, Li A, King J, Angst E,
Dawson DW, Park J, Reber HA, Hines OJ and Eibl G: Loss of
15-hydroxyprostaglandin dehydrogenase increases prostaglandin E2 in
pancreatic tumors. Pancreas. 39:332–339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tseng-Rogenski S, Gee J, Ignatoski KW,
Kunju LP, Bucheit A, Kintner HJ, Morris D, Tallman C, Evron J, Wood
CG, et al: Loss of 15-hydroxyprostaglandin dehydrogenase expression
contributes to bladder cancer progression. Am J Pathol.
176:1462–1468. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song HJ, Myung SJ, Kim IW, et al:
15-hydroxyprostaglandin dehydrogenase is downregulated and exhibits
tumor suppressor activity in gastric cancer. Cancer Invest.
29:257–265. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oshima H, Oshima M, Inaba K and Taketo MM:
Hyperplastic gastric tumors induced by activated macrophages in
COX-2/mPGES-1 transgenic mice. EMBO J. 23:1669–1678. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sierra JC, Hobbs S, Chaturvedi R, Yan F,
Wilson KT, Peek RM Jr and Polk DB: Induction of COX-2 expression by
Helicobacter pylori is mediated by activation of epidermal growth
factor receptor in gastric epithelial cells. Am J Physiol
Gastrointest Liver Physiol. 305:G196–G203. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Slomiany BL and Slomiany A: Induction in
gastric mucosal prostaglandin and nitric oxide by Helicobacter
pylori is dependent on MAPK/ERK-mediated activation of IKK-beta and
cPLA2: Modulatory effect of ghrelin. Inflammopharmacology.
21:241–251. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun WH, Yu Q, Shen H, Ou XL, Cao DZ, Yu T,
Qian C, Zhu F, Sun YL, Fu XL and Su H: Roles of Helicobacter pylori
infection and cyclooxygenase-2 expression in gastric
carcinogenesis. World J Gastroenterol. 10:2809–2813. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Arber N, Eagle CJ, Spicak J, Rácz I, Dite
P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, et al:
Celecoxib for the prevention of colorectal adenomatous polyps. N
Engl J Med. 355:885–895. 2006. View Article : Google Scholar : PubMed/NCBI
|
